Abstract 1178P
Background
Melanoma is the fifth most common cancer and, although rare, is the most common skin malignancy in those under 20 years old in the United States (US), with an average annual incidence rate (IR) of 5.5-6.0 cases per million. Since the 1970s, the incidence of pediatric melanoma has increased with an average annual percent change of 2–2.9% in the US. Epidemiological knowledge and predictors of melanoma among children and adolescents (age < 20 years) in Korea are limited.
Methods
Using data from National Health Insurance (NHI) database, we identified incident melanoma cases diagnosed at 0-19 years old during 2004-2019 in Korea, respectively. Using a joinpoint regression model, associations between demographic factors and melanoma incidence rates (IR) were evaluated by calculating incidence rate ratios and 95% confidence intervals (CI).
Results
We identified a total of 1160 patients (age < 20 years) with cutaneous malignant melanoma from 2004-2019. The overall average annual melanoma incidence was 0.22 per million (95% CI, 0.21-0.23) in Korea. It increased with age (age 0-4: 0.3, age 5-9: 0.6, age 10-14: 0.6, age 15-19: 07 per 100,000 persons) but there was no difference in IR according to sex. The age-adjusted incidence of melanoma decreased 4.5% yearly from 2004 to 2012 (95% CI, -8.9%–0.1%) but increased 12.6% yearly from 2012 to 2019 (95% CI, 5.9%–19.6%). A strong correlation between melanoma IR and nevi was confirmed (OR 85.4, 95% CI 67.97 - 106.40, P < 0.001) and this was also linked to the survival rate (5-year survival rate: 97.7% vs 91.9%, P = 0.044).
Conclusions
Although the incidence of melanoma in children and adolescent is very low, it is clear that it increases in Korea. To our knowledge, this is the first report to suggest that melanoma IR trends in children and adolescent are annually increasing in Korea. Most importantly, we must increase awareness and education amongst pediatricians, internists and the general population with regard to prevention and early diagnosis of melanoma for both children and adults. In addition, the physicians should include a complete skin examination for children with congenital nevi.
Clinical trial identification
none
Editorial acknowledgement
none
Legal entity responsible for the study
Jisu Oh.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1119P - Stage IIIA melanoma with isolated tumor cells in lymph nodes: Time for reviewing the AJCC v8 classification
Presenter: Teresa Amaral
Session: Poster session 13
1120P - Development and external validation of a clinical prediction model to predict recurrence-free survival and melanoma-specific survival in patients with melanoma after sentinel lymph node biopsy
Presenter: Robert Stassen
Session: Poster session 13
1121P - Interferon-gamma (IFNy) gene signature as a predictive biomarker for response in lactate dehydrogenase (LDH) low advanced melanoma patients
Presenter: Lotte Hoeijmakers
Session: Poster session 13
1122P - Neutrophil/lymphocyte ratio and systemic inflammatory index as prognostic biomarkers in metastatic melanoma patients under immune checkpoint inhibitors: Could any of them be used?
Presenter: Maria Menezes
Session: Poster session 13
1123P - Baseline tumor-infiltrating lymphocytes and response to immune checkpoint inhibition in advanced melanoma
Presenter: Mark Schuiveling
Session: Poster session 13
1124P - IL-6 as prognostic factor in adjuvant or metastatic skin cancer patients treated with immunotherapy: A deep biomarker analysis
Presenter: Domenico Mallardo
Session: Poster session 13
1125P - Identification of a subset of metastatic melanoma patients demonstrating germline determined insensitivity to immunotherapy
Presenter: Benjamin Fairfax
Session: Poster session 13
1126P - REtrospective Study of definitive therapy for head and neck mUcosal MElanoma: The RESUME study
Presenter: Motoo Nomura
Session: Poster session 13
1127P - Efficacy of immune checkpoint inhibitors (ICIs) in advanced mucosal melanoma (MM): A systematic review and meta-analysis
Presenter: James Pham
Session: Poster session 13
1128P - A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma
Presenter: Sapna Patel
Session: Poster session 13